文献速递心脏核医学

单光子发射计算机断层扫描/计算机断层扫描定量锝-99m焦磷酸摄取评估转甲状腺素蛋白心脏淀粉样变性中tafamidis治疗反应

Single-photon emission computed tomography/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis.
PubMed 文献 · J Nucl Cardiol · 2024-10-09

前瞻性单中心研究纳入22例接受tafamidis治疗的转甲状腺素蛋白心脏淀粉样变性患者,用锝-99m焦磷酸SPECT/CT定量全心和左心室示踪剂摄取。经最大主动脉SUV校正后,左心室总SUV下降36.9%、SUV体积下降38.7%、注射剂量百分比下降34.9%(均P≤0.0001),研究期间各项指标每月下降7.7%。

要点

  • 锝-99m焦磷酸SPECT/CT可定量全心和左心室淀粉样变负荷。
  • tafamidis治疗期间左心室总SUV经校正后下降36.9%(P≤0.0001)。
  • 尚需确定最佳定量指标并提高定量可重复性。

核心结论

  • 锝-99m焦磷酸SPECT/CT定量SUV显示tafamidis治疗期间闪烁显像淀粉样变负荷总体下降,但尚需额外工作确定最佳指标并提高定量可重复性。

研究设计与样本

  • 前瞻性单中心研究纳入22例接受tafamidis治疗的转甲状腺素蛋白心脏淀粉样变性患者,用锝-99m焦磷酸SPECT/CT定量全心和左心室示踪剂摄取。

主要发现

  • 22例患者年龄77.0±7.5岁、男性86.4%,tafamidis治疗15.3±4.0个月,基线至末次随访平均16.8±4.7个月。
  • 13例患者(59.1%)有多次随访淀粉样变检查。
  • 总SUV、SUV体积和注射剂量百分比出现统计学显著下降。
  • 经最大主动脉SUV校正后,左心室总SUV下降36.9%、SUV体积下降38.7%、注射剂量百分比下降34.9%(均P≤0.0001)。
  • 研究期间各项测量指标每月下降7.7%。

局限性

  • 原文结论指出尚需额外工作确定最佳指标并提高定量可重复性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiac imaging with bone-avid tracers for the diagnosis of transthyretin amyloid (ATTR) cardiac amyloidosis uses only limited quantification, but single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition can provide volumetric assessment with quantification of tracer uptake. Tafamidis is routinely used in the treatment of cardiac amyloidosis, but there are scant data on changes in imaging results during therapy. The purpose of this study was to perform a longitudinal assessment of Tc-99m-pyrophosphate (PYP) imaging to determine if tafamidis therapy results in any change in quantitative measures of tracer uptake. METHODS: The study incorporated a prospective, single-center study of ATTR patients being treated with tafamidis using Tc-99m-PYP SPECT/CT to quantify cardiac tracer uptake in the whole heart and left ventricle. Standardized uptake values (SUVs) were adjusted for blood pool activity. Comparison of baseline activity was made to values obtained approximately every 6 months during treatment. RESULTS: Twenty-two patients (77.0±7.5 years old, 86.4% male) were on tafamidis for 15.3±4.0 months, with an average time between baseline and final follow-up study of 16.8±4.7 months. Thirteen patients (59.1%) had multiple follow-up amyloid studies. Statistically significant reductions in total SUVs, SUV volume, and percentage of injected dose were seen. Adjusted for the maximal aortic SUV, the total SUV in the left ventricle decreased by 36.9%, the SUV volume by 38.7%, and the percentage of injected dose decreased by 34.9% (all P values≤0.0001). Over the study duration, there was a decrease of 7.7%/month in the measured metrics. CONCLUSION: The quantitative SUV measurements from Tc-99m-PYP SPECT/CT revealed an overall decrease in scintographic amyloid burden during the course of tafamidis therapy, but additional work is needed to determine the optimal metrics and improve the reproducibility of the quantification.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Godoy-Rivas C, Elsadany M, Jaiswal A, et al. Single-photon emission computed tomography/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis. J Nucl Cardiol. 2024. PMID: 39389529. doi:10.1016/j.nuclcard.2024.102056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。